Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — Q1 2025 Earnings Presentation
12 slides from Eurofins Scientific's earnings presentation, Apr 23, 2025
Slide 1: Q1 2025 Trading Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights • Reported revenues in Q1 2025 totalled €1,767m, an increase of 6.9% vs Q1 2024, driven by organic growth and acquisitions, despite a negative public working day impact. Q1 2025 • Organic revenue growth1,A was 3.9%, which incl
Slide 4: Revenue bridge
Revenue bridge (€m) 1,767 Q1 2025: +3.9%2 Q1 2025 excl. adjustment for PWD: +2.6% • FX tailwind of 1.2% due to strength of the US Dollar vs Euro in Q1 2025 vs Q1 2024 • Organic revenue growth1,A was 3.9% 1,698 in Q1 2025, which includes an adjustment for public working days of 1.2% • Eurofins sustai
Slide 5: Organic growth by activity
Organic growth by activity Revenues (€m) Commentary Organic revenue • Food and Feed Testing: continued stable growth in Europe, while North America experienced solid growth1,A growth. Life • Environment Testing: continued stable growth in Europe, while North America was affected by adverse +3.9%2 1,
Slide 6: 11 acquisitions closed in Q1 2025 to bolster our technological capabilities and global footprint
11 acquisitions closed in Q1 2025 to bolster our technological capabilities and global footprint Acquired companies generated revenues of over €160m in 2024 North America Europe Rest of the World 5 acquisitions 3 acquisitions 3 acquisitions Acquired: Acquired: Acquired: • Multiple Environment • SYNL
Slide 7: Capital allocation developments in Q1 2025
Capital allocation developments in Q1 2025 Continued • Continue the build out of its best-in-class, fully digital global laboratory network; on track for completion by 2027 strategic • Acquisitions: 11 acquisitions closed with proforma 2024 revenues of over €160m investments • Start-ups: launched 5
Slide 8: Objectives for FY 2025 and to FY 2027 confirmed
Objectives for FY 2025 and to FY 2027 confirmed • Eurofins is confirming its objectives for FY 2025 and FY 2027 as announced at the FY 2024 results presentation on 30 January 2025 • Mid-single-digit organic growth and potential average revenues from acquisitions of €250m consolidated at mid-year • A
Slide 9: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2025. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9
Slide 10: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2025. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 10
Slide 11: Breakdown of revenue by Operating Segment and by Area of Activity
Breakdown of revenue by Operating Segment and by Area of Activity Y-o-Y variation Organic €m Q1 2025 As % of total Q1 2024 As % of total % growth1,A,* Europe 893 51% 850 51% 5.0% 2.9% North America 685 39% 628 38% 9.0% 0.9% Rest of the World 189 11% 175 11% 8.1% 8.0% Total 1,767 100% 1,653 100% 6.9%
Slide 12: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items – include one-off costs from network expansion, integratio